Fisetin to Improve Vascular Function in Older Adults
Key claim: A pilot clinical trial is testing whether intermittent fisetin improves vascular endothelial function and reduces aortic stiffness in older adults, potentially by lowering mitochondrial oxidative stress, cellular senescence, and circulating SASP factors.
Abstract
This is a pilot clinical trial to test the efficacy of intermittent treatment with the flavonoid compound fisetin for improving vascular endothelial function and reducing aortic stiffness in older adults. This trial will also determine the potential mechanisms by which fisetin may improve vascular function, including by decreasing mitochondrial oxidative stress, cellular senescence and senescence-associated secretory phenotype (SASP) factors in circulation. Lastly, safety, tolerability and adherence of fisetin treatment will be assessed.
Why this matters
Fisetin has been carried largely by preclinical senolytic data and a few small human safety/feasibility trials; a pilot with prespecified vascular function endpoints plus senescence, SASP, and mitochondrial oxidative stress readouts is the kind of design that can start attaching human mechanistic signal to the senolytic-for-vascular-aging narrative. Whether it delivers depends on effect sizes at pilot scale, but it slots fisetin alongside D+Q, MitoQ, and acetate as candidate levers being tested with vascular-aging endpoints in older adults.